Alx Oncology Holdings (ALXO) executive compensation, 2026 proxy

Jason Lettmann, Chief Executive Officer, was paid $2.5M in 2025, down 63% from $6.6M the year before.

Filed
April 20, 2026
Annual meeting
June 10, 2026
Pay year
2025
Named executives
4
CEO total pay
$2.5M-63% vs prior year
CEO pay in equity
71%$1.7M in awards
Prior say-on-pay support
69%of votes cast
CEO Target Bonus
55%Percentage of annual base salary
Say-on-Pay Support
68.64%Previous advisory vote approval
CFO Base Salary
$490,000For fiscal 2025
Former CSO Severance
$650,000Pursuant to separation agreement

How Lettmann was paid

$2.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary29%Stock awards59%Option awards12%

Named executive officers

ExecutiveTotal
Jason LettmannChief Executive Officer$2,470,844
Harish ShantharamChief Financial Officer$1,700,673
Shelly WongSenior Vice President, Finance and Chief Accounting Officer$940,405
Jaume Pons, Ph.D.Former President and Chief Scientific Officer$973,729

What changed and why

  • $6.6MCEO total compensation decreased from $6,640,830 in 2024 to $2,470,844 in 2025.
  • $3.2MStock awards for the CEO decreased from $3,168,000 in 2024 to $1,447,488 in 2025.
  • $2.5MOption awards for the CEO decreased from $2,480,230 in 2024 to $298,856 in 2025.
  • Harish Shantharam joined the company as Chief Financial Officer in January 2025.
  • $650KJaume Pons received a severance payment of $650,000 following his departure in April 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.